HOUSTON — A new analysis highlights the high burden of insomnia across the Americas, with about 17% of adults suffering from this chronic sleep disorder.
“Our findings underscore the urgent need for enhanced clinical care pathways and policy interventions to effectively diagnose and treat insomnia. It is crucial to foster greater awareness of the critical role that sleep plays in overall health,” lead investigator Adam Benjafield, PhD, vice president for medical affairs at ResMed, Sydney, Australia, told Medscape Medical News.
“Insomnia not only affects individuals’ health and quality of life but also has broader implications for public health systems. Developing comprehensive care strategies and promoting education about sleep health could significantly improve outcomes for individuals suffering from insomnia disorder,” Benjafield said.
The findings were presented at SLEEP 2024: 38th Annual Meeting of the Associated Professional Sleep Societies.
Underdiagnosed, Undertreated
Sleep disruptions contribute to various medical problems, including cognitive impairment, reduced immune function, metabolic imbalance, and exacerbation of psychiatric conditions. While the prevalence of insomnia in developed countries like the United States and Canada is known, there is limited epidemiologic evidence, and no reliable estimate for the disorder across the Americas — especially in low- and middle-income countries.
The researchers used published nation-specific data to estimate the prevalence of adult insomnia disorder across the 55 countries defined by the United Nations as comprising the Americas.
Based on the available data, the researchers estimate that about 123 million adults across the Americas have insomnia disorder (16.8%) — with greater prevalence in women (73 million, 19.5%) than in men (50 million, 14%).
The nations with the greatest burden of insomnia disorder are the United States (37 million), Brazil (29 million), and Mexico (16 million).
“While our study did not specifically investigate trends over time due to its scope, evidence from other research suggests that insomnia is becoming more prevalent over the long term. This growing trend highlights the increasing need for awareness and intervention in managing sleep health,” Benjafield said.
Insomnia is underdiagnosed and undertreated due in part to a general lack of awareness about the importance of addressing sleep disorders and the fact that Cognitive-Behavioral Therapy for Insomnia (CBT-I), which is recommended as first-line treatment, is not widely accessible due to a shortage of trained CBT-I practitioners.
“Many individuals with insomnia struggle to find and receive this effective nonpharmacological treatment. Consequently, there is an over-reliance on pharmaceutical solutions, which are ideally used for short-term management but are often extended due to the lack of alternatives. These medications can lead to dependency and other side effects,” Benjafield said.
Ask About Sleep
Insomnia symptoms are a “common presenting complaint in doctors’ offices in the United States. The percentages in this poster show that insomnia disorder has a similar, high percent prevalence across countries in the Americas,” Boris Gilyadov, MD, assistant professor of pulmonary, critical care and sleep medicine at the Icahn School of Medicine at Mount Sinai in New York City, told Medscape Medical News.
“During preventive care visits and general physical exams, patients should be asked about the quality of their sleep. Patients may benefit from a referral to the sleep medicine clinic when appropriate,” said Gilyadov, who wasn’t involved in the study.
“CBT-I is the first-line treatment for chronic insomnia disorder and can be an effective treatment for most patients. An alternative to CBT-I, when it is not available, is digital CBT-I,” Gilyadov said.
“There are also behavioral therapies called BBT-I (brief behavioral treatment for insomnia) and ACT (acceptance and commitment therapy). These are therapies that may be offered by psychologists who specialize in the treatment of chronic insomnia disorder,” Gilyadov noted.
The study was conducted in collaboration with medXcloud and funded by ResMed. Benjafield is an employee of ResMed. Gilyadov had no relevant disclosures.
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Medscape – https://www.medscape.com/viewarticle/urgent-need-better-care-new-policies-lower-insomnia-burden-2024a1000bbm
